Effects of pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet

Teresa Delmoral, R. N. Goldberg, C. Suguihara, Octavio V. Martinez, William J Feuer, Eduardo Bancalari

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Pentoxifylline (PTXF) is a methylxanthine that modifies leukocyte function and inhibits cytokine release. To evaluate its effects on the cardiovascular manifestations of sepsis secondary to group B streptococci, 14 anesthetized, mechanically ventilated piglets were studied over a 240-min period. Animals were randomly assigned to a treatment group that received a PTXF bolus (20 mg/kg) followed by a continuous infusion of 5 mg/kg/h before and during group B streptococci (1 x 108 colony forming units/kg/min) administration and a control group that received saline as a placebo. Comparison of the hemodynamic measurements and arterial blood gases during the first 90 min of PTXF treatment with those of the control group resulted in the following 90 min values: systemic arterial blood pressure was significantly higher in the PTXF group (89 ± 10 versus 56 ± 30 mm Hg; p < 0.005) as was cardiac output (0.18 ± 0.04 versus 0.10 ± 0.07 L/kg/min; p < 0.005). Pulmonary vascular resistance remained lower in the PTXF-treated animals (135 ± 117 versus 248 ± 119 mm Hg/L/min/kg; p < 0.001), and these animals were less acidotic as measured by pH (7.07 ± 0.2 versus 7.31 ± 0.1; p < 0.05) and base deficit (- 15 ± 9 versus -5 ± 2 mmol/L; p < 0.05). Median survival time was significantly longer in the PTXF group (210 versus 90 min; p < 0.002). These data demonstrate that PTXF can ameliorate some of the deleterious hemodynamic manifestations of group B streptococci sepsis and result in improved survival in a young animal model.

Original languageEnglish
Pages (from-to)596-600
Number of pages5
JournalPediatric Research
Volume31
Issue number6
StatePublished - Jan 1 1992

Fingerprint

Pentoxifylline
Sepsis
Streptococcus agalactiae
Hemodynamics
Control Groups
Cardiac Output
Vascular Resistance
Arterial Pressure
Leukocytes
Stem Cells
Animal Models
Gases
Placebos
Cytokines
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Effects of pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet. / Delmoral, Teresa; Goldberg, R. N.; Suguihara, C.; Martinez, Octavio V.; Feuer, William J; Bancalari, Eduardo.

In: Pediatric Research, Vol. 31, No. 6, 01.01.1992, p. 596-600.

Research output: Contribution to journalArticle

@article{d13899b0a9da487e9f2b464760f69f9b,
title = "Effects of pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet",
abstract = "Pentoxifylline (PTXF) is a methylxanthine that modifies leukocyte function and inhibits cytokine release. To evaluate its effects on the cardiovascular manifestations of sepsis secondary to group B streptococci, 14 anesthetized, mechanically ventilated piglets were studied over a 240-min period. Animals were randomly assigned to a treatment group that received a PTXF bolus (20 mg/kg) followed by a continuous infusion of 5 mg/kg/h before and during group B streptococci (1 x 108 colony forming units/kg/min) administration and a control group that received saline as a placebo. Comparison of the hemodynamic measurements and arterial blood gases during the first 90 min of PTXF treatment with those of the control group resulted in the following 90 min values: systemic arterial blood pressure was significantly higher in the PTXF group (89 ± 10 versus 56 ± 30 mm Hg; p < 0.005) as was cardiac output (0.18 ± 0.04 versus 0.10 ± 0.07 L/kg/min; p < 0.005). Pulmonary vascular resistance remained lower in the PTXF-treated animals (135 ± 117 versus 248 ± 119 mm Hg/L/min/kg; p < 0.001), and these animals were less acidotic as measured by pH (7.07 ± 0.2 versus 7.31 ± 0.1; p < 0.05) and base deficit (- 15 ± 9 versus -5 ± 2 mmol/L; p < 0.05). Median survival time was significantly longer in the PTXF group (210 versus 90 min; p < 0.002). These data demonstrate that PTXF can ameliorate some of the deleterious hemodynamic manifestations of group B streptococci sepsis and result in improved survival in a young animal model.",
author = "Teresa Delmoral and Goldberg, {R. N.} and C. Suguihara and Martinez, {Octavio V.} and Feuer, {William J} and Eduardo Bancalari",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "31",
pages = "596--600",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Effects of pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet

AU - Delmoral, Teresa

AU - Goldberg, R. N.

AU - Suguihara, C.

AU - Martinez, Octavio V.

AU - Feuer, William J

AU - Bancalari, Eduardo

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Pentoxifylline (PTXF) is a methylxanthine that modifies leukocyte function and inhibits cytokine release. To evaluate its effects on the cardiovascular manifestations of sepsis secondary to group B streptococci, 14 anesthetized, mechanically ventilated piglets were studied over a 240-min period. Animals were randomly assigned to a treatment group that received a PTXF bolus (20 mg/kg) followed by a continuous infusion of 5 mg/kg/h before and during group B streptococci (1 x 108 colony forming units/kg/min) administration and a control group that received saline as a placebo. Comparison of the hemodynamic measurements and arterial blood gases during the first 90 min of PTXF treatment with those of the control group resulted in the following 90 min values: systemic arterial blood pressure was significantly higher in the PTXF group (89 ± 10 versus 56 ± 30 mm Hg; p < 0.005) as was cardiac output (0.18 ± 0.04 versus 0.10 ± 0.07 L/kg/min; p < 0.005). Pulmonary vascular resistance remained lower in the PTXF-treated animals (135 ± 117 versus 248 ± 119 mm Hg/L/min/kg; p < 0.001), and these animals were less acidotic as measured by pH (7.07 ± 0.2 versus 7.31 ± 0.1; p < 0.05) and base deficit (- 15 ± 9 versus -5 ± 2 mmol/L; p < 0.05). Median survival time was significantly longer in the PTXF group (210 versus 90 min; p < 0.002). These data demonstrate that PTXF can ameliorate some of the deleterious hemodynamic manifestations of group B streptococci sepsis and result in improved survival in a young animal model.

AB - Pentoxifylline (PTXF) is a methylxanthine that modifies leukocyte function and inhibits cytokine release. To evaluate its effects on the cardiovascular manifestations of sepsis secondary to group B streptococci, 14 anesthetized, mechanically ventilated piglets were studied over a 240-min period. Animals were randomly assigned to a treatment group that received a PTXF bolus (20 mg/kg) followed by a continuous infusion of 5 mg/kg/h before and during group B streptococci (1 x 108 colony forming units/kg/min) administration and a control group that received saline as a placebo. Comparison of the hemodynamic measurements and arterial blood gases during the first 90 min of PTXF treatment with those of the control group resulted in the following 90 min values: systemic arterial blood pressure was significantly higher in the PTXF group (89 ± 10 versus 56 ± 30 mm Hg; p < 0.005) as was cardiac output (0.18 ± 0.04 versus 0.10 ± 0.07 L/kg/min; p < 0.005). Pulmonary vascular resistance remained lower in the PTXF-treated animals (135 ± 117 versus 248 ± 119 mm Hg/L/min/kg; p < 0.001), and these animals were less acidotic as measured by pH (7.07 ± 0.2 versus 7.31 ± 0.1; p < 0.05) and base deficit (- 15 ± 9 versus -5 ± 2 mmol/L; p < 0.05). Median survival time was significantly longer in the PTXF group (210 versus 90 min; p < 0.002). These data demonstrate that PTXF can ameliorate some of the deleterious hemodynamic manifestations of group B streptococci sepsis and result in improved survival in a young animal model.

UR - http://www.scopus.com/inward/record.url?scp=0026552454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026552454&partnerID=8YFLogxK

M3 - Article

C2 - 1635822

AN - SCOPUS:0026552454

VL - 31

SP - 596

EP - 600

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 6

ER -